Source-grounded facts extracted from Azenta, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Azenta, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $145 million, EPS ($3.41). Guidance lowered.
“position Azenta for improved execution, greater consistency, and profitable long‐term value creation.” Second Quarter Fiscal 2026 Results - Continuing Operations • Revenue was $145 million, up 1% year over year. Organic revenue, which excludes a 3-percentage point impact from foreign exchange and a 1-percentage point from the acquisition of UK Biocentre Limited,”
Azenta, Inc. entered into Share Purchase Agreement with UK Biocentre Limited valued at GBP 20.5 million (effective 2026-03-04).
“On March 4, 2026, Azenta UK Ltd., a wholly owned subsidiary of Azenta, Inc. (“Azenta” or the “Company”) entered into a definitive Share Purchase Agreement (“Agreement”) under which Azenta UK Ltd. acquired all the issued and outstanding share capital of UK Biocentre Limited (“UK Biocentre”), a provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom.”
Azenta, Inc. entered into Share Purchase Agreement with Thelema S.À R.L. valued at USD 63,000,000 (effective 2025-12-23).
“On December 23, 2025, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc. (“Azenta” or the “Company”) entered into a definitive Sale and Purchase Agreement (“Share Purchase Agreement”) with Thelema S.À R.L. (“Thelema”) relating to the entire issued share capital of B Medical Systems S.À R.L. (“B Medical”), a subsidiary of Azenta Germany GmbH.”
Ephraim Starr was appointed as Senior Vice President, General Counsel and Secretary at Azenta, Inc..
“On May 15, 2025, the Company appointed Ephraim Starr as its Senior Vice President, General Counsel and Secretary to succeed Mr. Joseph.”
Jason W. Joseph departed as Senior Vice President, General Counsel and Secretary at Azenta, Inc..
“On May 12, 2025, Azenta, Inc. (the “Company”) and Jason W. Joseph, Senior Vice President, General Counsel and Secretary, agreed that Mr. Joseph would cease to serve in that role, effective May 15, 2025 and that Mr. Joseph’s employment with the Company would cease effective June 30, 2025.”
David Wang departed as President of Sample Management Solutions at Azenta, Inc..
“On April 7, 2025, Azenta, Inc. (the “Company”) and David Wang, President of Sample Management Solutions, agreed that Mr. Wang’s employment with the Company would cease effective April 9, 2025”
Herman Cueto departed as Executive Vice President and Chief Financial Officer at Azenta, Inc..
“Herman Cueto, who is departing from his role at the Company.”
Lawrence Lin was appointed as Executive Vice President and Chief Financial Officer at Azenta, Inc..
“appointed Lawrence Lin as its Executive Vice President and Chief Financial Officer, effective as of Effective Time”
Quentin Koffey was appointed as Director at Azenta, Inc..
“Pursuant to the Cooperation Agreement, on November 1, 2024, the Board appointed Mr. Koffey as a member of the Board, effective November 1, 2024, with an initial term expiring at the 2025 Annual Meeting.”
Alan Malus was appointed as Director at Azenta, Inc..
“Effective November 1, 2024, the Board appointed each of Mr. Cornog and Mr. Malus (together with Mr. Koffey, the “New Directors”) as a member of the Board, with an initial term expiring at the 2025 Annual Meeting.”
William Cornog was appointed as Director at Azenta, Inc..
“Effective November 1, 2024, the Board appointed each of Mr. Cornog and Mr. Malus (together with Mr. Koffey, the “New Directors”) as a member of the Board, with an initial term expiring at the 2025 Annual Meeting.”
Stephen Schwartz departed as President and Chief Executive Officer at Azenta, Inc..
“succeed the Company’s current President and Chief Executive Officer, Dr. Stephen Schwartz, who as previously announced is retiring effective as of the Start Date”
John Marotta was appointed as Member of the Board at Azenta, Inc..
“the Board also increased the size of the Board from eight to nine members and appointed Mr. Marotta as a member of the Board”
Stephen Schwartz resigned as director at Azenta, Inc..
“Dr. Schwartz resigned as a director of the Company effective as of May 7, 2024”
Stephen Schwartz retired as President and Chief Executive Officer at Azenta, Inc..
“Dr. Stephen Schwartz informed the Company of his intention to retire from his position as President and Chief Executive Officer and a director of the Company”
Azenta, Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $159 million, net income $ (2.47) diluted EPS from continuing operations, EPS $ (2.47) diluted EPS from continuing operations. Guidance lowered.
“Day in March, we are confident in our position and the market opportunity which we are uniquely positioned to capture.” Second Quarter Fiscal 2024 Results ● Revenue was $159 million, up 7% year over year. Organic revenue, which excludes the impacts from foreign exchange, was also up 7% year over year, with a nominal benefit from foreign exchange tailwinds.”
Azenta, Inc. reported the first quarter ended December 31, 2023 results: revenue $ 154, net income $ (0.28), EPS $(0.28) per diluted share. Guidance reaffirmed.
“in millions, except per share data December 31, September 30, December 31, Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 154 $ 172 $ 178 (10) % (13) % Organic growth (15) % Sample Management Solutions $ 79 $ 82 $ 75 (3) % 5 % Multiomics $ 63 $ 61 $ 61 3”
Azenta, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered accounting firm for the 2024 fiscal year at the 2024-01-30 meeting.
“4. Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered accounting firm for the 2024 fiscal year For Against Abstain 52,209,022 164,934 36,397”
Azenta, Inc. shareholders approved To approve, on an advisory basis, the frequency of holding an advisory vote on executive compensation at the 2024-01-30 meeting.
“3. To approve, on an advisory basis, the frequency of holding an advisory vote on executive compensation. 1 Year 2 Years 3 Years Broker Non-Votes 48,230,323 10,459 1,854,680 2,314,891”
Azenta, Inc. shareholders approved Approval, by a non-binding advisory vote, of the overall compensation of the Company’s named executive officers at the 2024-01-30 meeting.
“2. Approval, by a non-binding advisory vote, of the overall compensation of the Company’s named executive officers For Against Abstain Broker Non-Votes 49,109,585 900,374 123,893 2,276,501”
Azenta, Inc. shareholders approved Election of Directors at the 2024-01-30 meeting.
“1. Election of Directors Nominees For Withold Broker Non-Votes Edward Bousa 48,072,463 2,061,389 2,276,501 Frank E. Casal 48,503,942 1,629,910 2,276,501 Robyn C. Davis 49,082,282 1,051,570 2,276,501 Didier Hirsch 49,866,149 267,703 2,276,501 Martin Madaus 47,247,939 2,885,913 2,276,501 Erica J. McLaughlin 48,281,569 1,852,283 2,276,501 Tina S. Nova 47,415,765 2,718,087 2,276,501 Michael Rosenblatt 49,537,175 596,677 2,276,501 Stephen S. Schwartz 49,625,351 508,501 2,276,501”
Ellen M. Zane departed as Director at Azenta, Inc..
“On January 10, 2024, Ellen M. Zane notified Azenta, Inc. (the “Company”) that she has decided not to stand for election to the Board of Directors of the Company (the “Board”) at the 2024 Annual Meeting of the Company’s Stockholders to be held on Tuesday, January 30, 2024”
Azenta, Inc. updated its fiscal quarter and year ended September 30, 2023 guidance (raised).
“On November 13, 2023, Azenta, Inc. (“Azenta” or the “Company”) announced via press release its financial results for the fiscal quarter and year ended September 30, 2023.”
Lindon Robertson departed as Executive Vice President and Chief Financial Officer at Azenta, Inc..
“to succeed the Company’s current Executive Vice President and Chief Financial Officer, Lindon Robertson, who is retiring.”
Herman Cueto was appointed as Executive Vice President and Chief Financial Officer at Azenta, Inc..
“On September 25, 2023, Azenta, Inc. (the “Company”) appointed Herman Cueto as its Executive Vice President and Chief Financial Officer, effective as of October 16, 2023”
Azenta, Inc. reported fourth quarter of fiscal 2023 results: revenue $155 to $173 million, EPS ($0.02) to $0.06. Guidance initiated.
“Total revenue is expected to be in the range of $155 to $173 million.”
Azenta, Inc. reported third quarter ended June 30, 2023 results: revenue $166 million, EPS ($0.04).
“confident in the unique value we bring to our customer partnerships across pharmaceutical, biotech, and academic institutions.” Third Quarter Fiscal 2023 Results ● Revenue was $166 million, up 25% year over year and 12% sequentially. Organic revenue increased 2% year over year, which excludes the impacts from foreign exchange headwinds of less than 1 percent and”
Azenta, Inc. reported financial results for the second quarter ended March 31, 2023.
“On May 9, 2023, Azenta, Inc. (“Azenta” or the “Company”) announced via press release its financial results for the fiscal quarter ended March 31, 2023.”
Azenta, Inc. reported first quarter ended December 31, 2022 results: revenue $178 million, EPS $ (0.15). Guidance initiated.
“● Reported Q1’23 Revenue of $178 Million and Growth of 28% Year-Over-Year”
Azenta, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered accounting firm for the 2023 fiscal year at the 2023-01-31 meeting.
“The stockholders elected each of the Company’s nominees for director; approved, by a non-binding advisory vote, the overall compensation of the Company’s named executive officers; and ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered accounting firm for the 2023 fiscal year.”
Azenta, Inc. shareholders approved Approval, by a non-binding advisory vote, of the overall compensation of the Company’s named executive officers at the 2023-01-31 meeting.
“The stockholders elected each of the Company’s nominees for director; approved, by a non-binding advisory vote, the overall compensation of the Company’s named executive officers; and ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered accounting firm for the 2023 fiscal year.”
Azenta, Inc. shareholders approved Election of Directors at the 2023-01-31 meeting.
“The stockholders elected each of the Company’s nominees for director; approved, by a non-binding advisory vote, the overall compensation of the Company’s named executive officers; and ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered accounting firm for the 2023 fiscal year.”
Azenta, Inc. entered into ASR Agreement with JPMorgan Chase Bank, National Association valued at $500.0 million (effective 2022-11-23).
“On November 23, 2022, as part of Azenta, Inc.’s (the “Company”) recently authorized stock repurchase program, the Company entered into an accelerated share repurchase agreement (the “ASR Agreement”) with JPMorgan Chase Bank, National Association (the “Dealer”) to repurchase an aggregate of up to $500.0 million of the Company’s common stock, par value $0.01 per share (the “Common Stock”).”
Azenta, Inc. reported the fiscal year ended September 30, 2022 results: revenue $555 million, EPS $(0.15).
“● Revenue for fiscal 2022 was $555 million, up 8% year over year.”
Azenta, Inc. reported the fourth quarter ended September 30, 2022 results: revenue $138 million, EPS $(0.07).
“● Revenue was $138 million, flat year over year and up 4% sequentially.”
Alfred Woollacott, III departed as Director at Azenta, Inc..
“On November 11, 2022, each of Mark S. Wrighton and Alfred Woollacott, III informed the Company that they will be retiring from the Board of Directors (the “Board”) of the Company and do not intend to stand for re-election to the Board at the upcoming 2023 annual meeting of stockholders.”
Mark S. Wrighton departed as Director at Azenta, Inc..
“On November 11, 2022, each of Mark S. Wrighton and Alfred Woollacott, III informed the Company that they will be retiring from the Board of Directors (the “Board”) of the Company and do not intend to stand for re-election to the Board at the upcoming 2023 annual meeting of stockholders.”
Matthew McManus departed as Chief Operating Officer at Azenta, Inc..
“On October 12, 2022, Azenta, Inc. (the “Company”) and Matthew McManus agreed that Mr. McManus would no longer serve as the Company’s Chief Operating Officer effective as of October 14, 2022.”
Vandana Sriram was appointed as Principal Accounting Officer at Azenta, Inc..
“As a result of Mr. Pietrantoni’s departure, Azenta appointed Vandana Sriram, age 48, Azenta’s current Vice President, Finance, and Corporate Controller, as Azenta’s Principal Accounting Officer, effective as of the closing of the Disposition.”
David Pietrantoni departed as Vice President, Finance and Corporate Controller and Principal Accounting Officer at Azenta, Inc..
“Both David E. Jarzynka, President, Brooks Semiconductor Solutions Group, and David Pietrantoni, Vice President, Finance and Corporate Controller and Principal Accounting Officer, continued with the Automation Business and, as a result, their employment with Azenta ended as of the closing of the Disposition on February 1, 2022.”
David E. Jarzynka departed as President, Brooks Semiconductor Solutions Group at Azenta, Inc..
“Both David E. Jarzynka, President, Brooks Semiconductor Solutions Group, and David Pietrantoni, Vice President, Finance and Corporate Controller and Principal Accounting Officer, continued with the Automation Business and, as a result, their employment with Azenta ended as of the closing of the Disposition on February 1, 2022.”
Frank E. Casal was appointed as Director at Azenta, Inc..
“On November 2, 2021, the board of directors (the “Board”) of Brooks Automation, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Frank E. Casal to fill the vacancy.”
Guojuan (Amy) Liao departed as President, Life Sciences Services at Azenta, Inc..
“On October 4, 2021, Brooks Automation, Inc. (“Brooks”) and Guojuan (Amy) Liao agreed that Dr. Liao will no longer serve as President, Life Sciences Services effective as of October 11, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.